Barry J. Simon - 20 Feb 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Reporting relationship: Director
Issuer ticker: IBRX
Reported as of: 20 Feb 2026
Net transaction value: -$1,836,028
SEC form: 4
Accepted by SEC: 24 Feb 2026, 20:03:46 UTC
Prior SEC filing: 21 Jan 2026
Next SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Philip LoScalzo, as Attorney-in-Fact

Key filing fact

Barry J. Simon filed Form 4 for ImmunityBio, Inc. (IBRX) on 24 Feb 2026.

Key facts

This page summarizes Barry J. Simon's Form 4 filing for ImmunityBio, Inc. (IBRX).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2026, 20:03.

Change

Previous filing in this sequence was filed on 21 Jan 2026.
Current net transaction value: -$1,836,028.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001647994 Primary reporting owner

Simon Barry J.

Relationship: Director
Address: C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO
Signature: /s/ Philip LoScalzo, as Attorney-in-Fact
Signature date: 24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IBRX transaction

Common Stock

Sale

Transaction value: $92,500
Shares: -10,000
Change %: -0.32%
Price: $9.25
Shares after: 3,081,604
Date: 20 Feb 2026
Ownership: Direct
Footnotes: F1

IBRX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +15,243
Change %: +0.49%
Price: $0.000000
Shares after: 3,096,847
Date: 22 Feb 2026
Ownership: Direct
Footnotes: F2

IBRX transaction

Common Stock

Tax liability

Transaction value: $52,426
Shares: -6,026
Change %: -0.19%
Price: $8.70
Shares after: 3,090,821
Date: 22 Feb 2026
Ownership: Direct
Footnotes: F3

IBRX transaction

Common Stock

Sale

Transaction value: $1,691,102
Shares: -165,000
Change %: -5.3%
Price: $10.25
Shares after: 2,925,821
Date: 23 Feb 2026
Ownership: Direct
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBRX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -15,243
Change %: -50%
Price: $0.000000
Shares after: 15,245
Date: 22 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,243
Exercise price
Footnotes: F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

Footnote F3

On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

Footnote F4

Represents the weighted average share price of an aggregate total of 165,000 shares sold in the price range of $9.89 to $10.635 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F5

Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.